These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10875003)

  • 1. Clinical research strategies in biotechnology.
    Vincent-Gattis M; Webb C; Foote M
    Biotechnol Annu Rev; 2000; 5():259-67. PubMed ID: 10875003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
    Ionan AC; Clark J; Travis J; Amatya A; Scott J; Smith JP; Chattopadhyay S; Salerno MJ; Rothmann M
    Ther Innov Regul Sci; 2023 May; 57(3):436-444. PubMed ID: 36459346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of natural products in drug discovery and development in the new millennium.
    Harvey A
    IDrugs; 2010 Feb; 13(2):70-2. PubMed ID: 20127553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The history of regulatory system for plasma fractionation products in the United States].
    Fukuzawa M; Tsutani K
    Yakushigaku Zasshi; 2014; 49(2):205-13. PubMed ID: 25799842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory concerns in the development of biologic-biomaterial combinations. United States Food and Drug Administration.
    Chapekar MS
    J Biomed Mater Res; 1996; 33(3):199-203. PubMed ID: 8864892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics.
    Ogasawara K; Breder CD; Lin DH; Alexander GC
    Clin Ther; 2018 Jan; 40(1):95-102.e2. PubMed ID: 29273471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical pharmacologic and toxicologic considerations for evaluating biologic products.
    Weissinger J
    Regul Toxicol Pharmacol; 1989 Dec; 10(3):255-63. PubMed ID: 2602582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action.
    Hirsch IB; Martinez J; Dorsey ER; Finken G; Fleming A; Gropp C; Home P; Kaufer DI; Papapetropoulos S
    Clin Ther; 2017 May; 39(5):1064-1076. PubMed ID: 28413148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.